Phase 1 trial evaluates clinical activity of tobemstomig in CPI-experienced melanoma, suggesting therapeutic potential for earlier treatment.
Tobemstomig had a tolerable and manageable safety profile across various advanced solid tumor indications. The encouraging antitumor activity associated with pharmacodynamic activity, and proof-of-mechanism in CPI-experienced melanoma patients, indicates the therapeutic potential of tobemstomig and supports further investigation in earlier disease treatment settings.
No takes yet. Share an insight, caveat, or question.
Garralda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: